Forma Therapeutics Holdings LLC has vowed to stay independent, even while satisfying venture backers. Its latest tie-up with Johnson & Johnson subsidiary [Janssen Pharmaceutical Ltd.] will allow the company to develop innovative cancer treatments while eventually having a hand in the commercialization.
Forma announced Jan. 10 that it has signed an agreement with Janssen to discover, develop, and commercialize novel compounds based...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?